Related Experiment Video
Updated: Jun 24, 2025

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
Classification of Mild Cognitive Impairment and Alzheimer's Disease Using Manual Motor Measures
Vincent Koppelmans1,2, Marit F L Ruitenberg3,4, Sydney Y Schaefer5
1Department of Psychiatry, University of Utah, Salt Lake City, Utah, USA.
Introduction:
Manual motor problems have been reported in mild cognitive impairment (MCI) and Alzheimer's disease (AD), but the specific aspects that are affected, their neuropathology, and potential value for classification modeling is unknown. The current study examined if multiple measures of motor strength, dexterity, and speed are affected in MCI and AD, related to AD biomarkers, and are able to classify MCI or AD.
Methods:
Fifty-three cognitively normal (CN), 33 amnestic MCI, and 28 AD subjects completed five manual motor measures: grip force, Trail Making Test A, spiral tracing, finger tapping, and a simulated feeding task. Analyses included (1) group differences in manual performance; (2) associations between manual function and AD biomarkers (PET amyloid β, hippocampal volume, and APOE ε4 alleles); and (3) group classification accuracy of manual motor function using machine learning.
Results:
Amnestic MCI and AD subjects exhibited slower psychomotor speed and AD subjects had weaker dominant hand grip strength than CN subjects. Performance on these measures was related to amyloid β deposition (both) and hippocampal volume (psychomotor speed only). Support vector classification well-discriminated control and AD subjects (area under the curve of 0.73 and 0.77, respectively) but poorly discriminated MCI from controls or AD.
Conclusion:
Grip strength and spiral tracing appear preserved, while psychomotor speed is affected in amnestic MCI and AD. The association of motor performance with amyloid β deposition and atrophy could indicate that this is due to amyloid deposition in and atrophy of motor brain regions, which generally occurs later in the disease process. The promising discriminatory abilities of manual motor measures for AD emphasize their value alongside other cognitive and motor assessment outcomes in classification and prediction models, as well as potential enrichment of outcome variables in AD clinical trials.
Insights
Psychomotor speed is reduced in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Manual motor tasks show potential for classifying AD, but not MCI, and correlate with Alzheimer's biomarkers.
Area of Science:
- Neurology
- Neuroscience
- Biomarkers
Background:
- Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are associated with manual motor deficits.
- Specific motor impairments, their neuropathological basis, and classification potential remain unclear.
Purpose of the Study:
- To investigate if manual motor strength, dexterity, and speed are affected in MCI and AD.
- To determine the relationship between motor function and AD biomarkers.
- To assess the utility of manual motor function for classifying MCI and AD.
Main Methods:
- Fifty-three cognitively normal (CN), 33 amnestic MCI, and 28 AD subjects performed five manual motor tasks.
- Analyses included group differences, correlations with AD biomarkers (amyloid β PET, hippocampal volume, APOE ε4), and machine learning classification.
- Manual motor measures included grip force, Trail Making Test A, spiral tracing, finger tapping, and a simulated feeding task.
Main Results:
- Amnestic MCI and AD groups showed slower psychomotor speed compared to CN.
- AD subjects exhibited weaker dominant hand grip strength than CN subjects.
- Motor performance correlated with amyloid β deposition and, for psychomotor speed, with hippocampal volume.
Conclusions:
- Psychomotor speed is impaired in MCI and AD, while grip strength and spiral tracing are preserved.
- Motor deficits are linked to amyloid β deposition and brain atrophy, suggesting later-stage disease involvement.
- Manual motor measures show promise for AD classification and could enhance clinical trials.

